Sysmex

Sysmex Corporation

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. The company employs more than 10,000 employees worldwide. Sysmex Corporation is listed in the Prime Market on the Tokyo Stock Exchange.

Content by Sysmex Corporation

Fluorescence in situ hybridization cancer cells
| 3 min read
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A 3D rendering illustrates a sandwich ELISA technique, where antigen detection is achieved between two layers of antibodies: a capture antibody and a detection antibody
Learn the key characteristics that determine whether an immunoassay generates accurate and reproducible data.
Illustration of translucent Y-shaped antibodies floating in a soft blue and green background, representing antibody research, development, and biomedical science.
Explore how antibody accessibility and custom development strategies can influence the pace and success of translational research.
Digital illustration of a glowing DNA double helix surrounded by interconnected circuit-like lines on a dark blue background.
Learn the key differences between chemical and enzymatic approaches to synthetic DNA production and their implications for modern research.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue